Early Phase 1
Completed N=8
Effect of Probenecid on Synovial Fluid ATP Levels in CPPD
Calcium Pyrophosphate Deposition Disease
Source: ClinicalTrials.gov NCT02243631 ↗
Enrolled (actual)
8
Serious AEs
0.0%
Results posted
Jul 2022
Primary outcomePrimary: ATP Levels in Synovial Fluid — 4.4; 31.4 nanomoles/ml
Summary
This study will investigate the hypothesis that probenecid, a medication currently used for gout, reduces levels of ATP in the joint fluid of patients with calcium pyrophosphate deposition disease (CPPD), another common type of crystal-related arthritis. There is good evidence that CPPD results from an excess of ATP in joints. The investigators will measure levels of ATP in joint fluid before and after 5 days of treatment with probenecid. This study will serve to rationalize larger studies of probenecid in CPPD.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY ATP Levels in Synovial Fluid |
4.4; 31.4 | — |
Eligibility Criteria
Inclusion Criteria
- Age >21 years,
- CPPD diagnosed by Ryan /McCarty criteria
- Joint effusion in a shoulder or knee
Exclusion Criteria
- Inability to sign informed consent
- Age stage 2)
- Blood dyscrasias
- Current use of drugs which interact with probenecid
- Concurrent gout
- Active infection, including bacteremia and overlying cellulitis
- Recent joint trauma
- Intra-articular corticosteroids in the affected joint within three months
Data sourced from ClinicalTrials.gov (NCT02243631). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.